MMED vs TFX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MMED · MiniMed Group$16.01 ▼ 1.54%
TFX · Teleflex$161.58 ▼ 1.11%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MMED +0.9%
- TFX +39.3%
Head to head
| Metric | MMED | TFX |
|---|---|---|
| Price | $16.01 | $161.58 |
| Change today | ▼ 1.54% | ▼ 1.11% |
| Market cap | $4.50B | $6.41B |
| Return, 3 months | -19.7% | +22.5% |
| Return, year to date | – | +33.5% |
| Return, 1 year | – | +56.8% |
| P/E (TTM) | – | 21.3 |
| P/B | 1.2 | 1.8 |
| P/E percentile vs own 5y | 34th | 22nd |
| Dividend yield | – | 0.84% |
| Revenue growth (YoY, latest qtr) | +16.6% | +0.1% |
| Net profit growth (YoY) | +100.0% | +326.8% |
| Gross margin | 53.9% | 58.3% |
| Operating margin | -5.0% | 11.2% |
| Net margin | -9.7% | 13.5% |
| Return on equity | -8.7% | 8.3% |
| Analyst target vs. price | +65.0% | +3.9% |
| Analyst buy share | 85% | 75% |
| RSI (14) | 37 | 75 |
| 30-day volatility | 64.9% | 29.4% |
| Max drawdown, 1 year | -41.6% | -23.6% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- TFX is the largest of the group by market value.
- MMED is growing revenue fastest.
- TFX keeps the most profit per dollar of sales.
- TFX has been the calmest stock over the last 30 days.